Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Nureca
Quarter-by-quarter operating performance
| Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 27.79 | 21.23 | 21.23 | 31.35 | 22.37 | 16.97 | 20.27 | 31.19 | 26.46 | 31.74 | 34.18 | 37.74 | 39.64 |
| Expenses + | 28.71 | 24.69 | 24.13 | 29.97 | 26.62 | 21.40 | 22.63 | 33.54 | 30.47 | 30.54 | 34.74 | 34.47 | 36.39 |
| Operating Profit | -0.92 | -3.46 | -2.90 | 1.38 | -4.25 | -4.43 | -2.36 | -2.35 | -4.01 | 1.20 | -0.56 | 3.27 | 3.25 |
| OPM % | -3.31% | -16.30% | -13.66% | 4.40% | -19.00% | -26.10% | -11.64% | -7.53% | -15.15% | 3.78% | -1.64% | 8.66% | 8.20% |
| Other Income + | 1.90 | 2.15 | 2.67 | 3.20 | 5.90 | -1.26 | 5.79 | 3.17 | 1.48 | 1.99 | 2.57 | 2.32 | 2.19 |
| Interest | 0.11 | 0.10 | 0.12 | 0.08 | 0.11 | 0.18 | 0.15 | 0.27 | 0.18 | 0.62 | 0.25 | 0.46 | 0.28 |
| Depreciation | 0.60 | 0.56 | 0.58 | 0.59 | 0.59 | 0.60 | 0.66 | 0.62 | 0.54 | 0.52 | 0.53 | 0.54 | 0.50 |
| Profit before tax | 0.27 | -1.97 | -0.93 | 3.91 | 0.95 | -6.47 | 2.62 | -0.07 | -3.25 | 2.05 | 1.23 | 4.59 | 4.66 |
| Tax % | -11.11% | -22.34% | -23.66% | 25.83% | 82.11% | -35.86% | 36.64% | 585.71% | -13.85% | -20.00% | 34.15% | 21.13% | 19.96% |
| Net Profit + | 0.30 | -1.53 | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.80 | 2.47 | 0.81 | 3.63 | 3.73 |
| EPS in Rs | 0.30 | -1.53 | -0.71 | 2.89 | 0.17 | -4.15 | 1.66 | -0.48 | -2.80 | 2.47 | 0.81 | 3.63 | 3.91 |
Financials of Nureca
Annual income statement trend
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|
| Sales + | 62 | 99 | 213 | 256 | 111 | 92 | 110 | 143 |
| Expenses + | 53 | 90 | 152 | 200 | 126 | 102 | 117 | 136 |
| Operating Profit | 9 | 10 | 62 | 56 | -15 | -10 | -8 | 7 |
| OPM % | 15% | 10% | 29% | 22% | -13% | -11% | -7% | 5% |
| Other Income + | 0 | 0 | 3 | 8 | 7 | 11 | 12 | 9 |
| Interest | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Profit before tax | 9 | 9 | 62 | 61 | -11 | -3 | 1 | 13 |
| Tax % | 30% | 26% | 26% | 26% | -23% | -30% | 37% | |
| Net Profit + | 6 | 6 | 46 | 45 | -8 | -2 | 1 | 11 |
| EPS in Rs | 6,230.00 | 6,400.00 | 46.37 | 44.96 | -8.25 | -1.79 | 0.85 | 10.82 |
| Dividend Payout % | 0% | 0% | 4% | 7% | 0% | 0% | 0% |
Financials of Nureca
Capital structure and asset base
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 8 | 15 | 153 | 193 | 185 | 183 | 184 | 189 |
| Borrowings + | 0 | 10 | 4 | 4 | 3 | 3 | 5 | 5 |
| Other Liabilities + | 15 | 9 | 19 | 12 | 8 | 10 | 11 | 21 |
| Total Liabilities | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 225 |
| Fixed Assets + | 1 | 1 | 4 | 10 | 9 | 7 | 9 | 14 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 33 | 59 | 94 | 1 | 8 |
| Other Assets + | 23 | 33 | 182 | 175 | 139 | 104 | 200 | 203 |
| Total Assets | 24 | 34 | 186 | 219 | 207 | 205 | 210 | 225 |
Financials of Nureca
Operating, investing and financing cash movement
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 0 | -8 | 35 | 1 | 10 | -3 | -19 |
| Cash from Investing Activity + | -0 | -0 | -110 | -3 | -16 | 18 | 8 |
| Cash from Financing Activity + | -0 | 8 | 92 | -7 | -2 | -1 | -0 |
| Net Cash Flow | 0 | -0 | 17 | -9 | -8 | 14 | -11 |
| Free Cash Flow | 0 | -8 | 34 | -5 | 10 | -4 | -21 |
| CFO/OP | 4% | -82% | 81% | 35% | -96% | 39% | 234% |
Financials of Nureca
Working capital efficiency and return ratios
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 47 | 6 | 4 | 14 | 6 | 11 |
| Inventory Days | 123 | 93 | 135 | 174 | 167 | 186 | 214 |
| Days Payable | 89 | 33 | 32 | 13 | 24 | 31 | 35 |
| Cash Conversion Cycle | 87 | 107 | 109 | 165 | 157 | 161 | 190 |
| Working Capital Days | 45 | 85 | 61 | 109 | 156 | 176 | 434 |
| ROCE % | 57% | 67% | 33% | -6% | -4% | -1% |
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients. Key concall takeaways from QMS…
PAT grew 23.8% y-o-y in Q1 FY27, showing healthy bottom-line growth (Page 4). Key concall takeaways from Laxmi Dental Ltd's Q1 FY27 earnings call — and how it…
Plastic labware market is expanding faster than glass, currently at INR1,200 crores, signaling long-term sector growth opportunities. Key concall takeaways…